Loading
HERBY asked whether adding the anti-blood-vessel antibody bevacizumab to radiotherapy and temozolomide would help children with high-grade brain tumours; it did not delay the tumours returning, so the drug is not part of standard treatment for these children.
HERBY was an open-label randomised phase 2 trial in children and adolescents with newly diagnosed high-grade glioma outside the brainstem. After surgery, patients received radiotherapy with concurrent and adjuvant temozolomide, with or without bevacizumab.
Adding bevacizumab did not improve event-free survival, the primary endpoint, as judged by central review, and did not improve overall survival. The trial did produce one of the best-characterised molecular cohorts of paediatric high-grade glioma; its biology sub-study showed that histone H3 and IDH mutation status, rather than histology, separated the outcomes, which fed into the WHO classification of these tumours.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
124 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival (central radiology review)primary | Bevacizumab + radiotherapy + temozolomide | 62 | 8.2 months | 1.44 | 0.13 | link |
| Radiotherapy + temozolomide | 59 | 11.8 months | ||||
| Overall survival | Bevacizumab + radiotherapy + temozolomide | 62 | Medians not reported in the abstract | 1.23 (0.72 to 2.09) | - | link |
| Radiotherapy + temozolomide | 59 | - | ||||
| Serious adverse events | Bevacizumab + radiotherapy + temozolomide | 62 | 58% | - | - | link |
| Radiotherapy + temozolomide | 59 | 48% |
Shares Temozolomide, Roche / Genentech, Anti-angiogenic therapy, Glioma & glioblastoma and the tag subtype-trials.
Shares Temozolomide, Glioma & glioblastoma and the tag subtype-trials.
Shares Anti-angiogenic therapy, Monoclonal antibodies and the tag subtype-trials.
Shares Temozolomide, Glioma & glioblastoma and the tag subtype-trials.
Shares Roche / Genentech, Monoclonal antibodies and the tag subtype-trials.
Shares Anti-angiogenic therapy and the tag subtype-trials.
Shares Roche / Genentech and the tag subtype-trials.
Shares Roche / Genentech and the tag subtype-trials.